GW Pharmaceuticals Plc (GWPH) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
SOVEREIGN HOUSE HISTON, CAMBRIDGE CB24 9BZ, 00000 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 3/31/2021 MRQ | 12/31/2020 | 12/31/2019 | 9/30/2018 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 486,752 | 536,933 | 354,913 | |||
| Cash and cash equivalents | 486,752 | 536,933 | 354,913 | |||
| Receivables | 71,168 | 48,883 | 2,122 | |||
| Inventory, net of allowances, customer advances and progress billings | 129,138 | 85,528 | 19,061 | |||
| Inventory | 129,138 | 85,528 | 19,061 | |||
| Other undisclosed current assets | 42,472 | 28,292 | 14,615 | |||
| Total current assets: | 729,530 | 699,636 | 390,711 | |||
| Noncurrent Assets | ||||||
| Finance lease, right-of-use asset, after accumulated amortization | 5,571 | ✕ | ||||
| Operating lease, right-of-use asset | 25,118 | 24,916 | ✕ | |||
| Property, plant and equipment | 143,767 | 127,765 | 82,381 | |||
| Intangible assets, net (including goodwill) | 12,524 | 6,959 | 6,959 | |||
| Goodwill | 6,959 | 6,959 | 6,959 | |||
| Intangible assets, net (excluding goodwill) | 5,565 | |||||
| Deferred income tax assets | 20,777 | ✕ | ||||
| Other noncurrent assets | 7,795 | 4,850 | 3,150 | |||
| Deferred tax assets, net | ✕ | ✕ | ✕ | 7,334 | ||
| Other undisclosed noncurrent assets | 12,552 | |||||
| Total noncurrent assets: | 209,981 | 182,613 | 99,824 | |||
| TOTAL ASSETS: | 939,511 | 882,249 | 490,535 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities | 150,596 | 109,801 | 57,865 | |||
| Taxes payable | 877 | 437 | 1,385 | |||
| Accounts payable | 21,870 | 9,990 | 9,741 | |||
| Accrued liabilities | 127,849 | 99,374 | 46,739 | |||
| Other liabilities | 9,210 | 7,760 | 804 | |||
| Total current liabilities: | 159,806 | 117,561 | 58,669 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 27,581 | 27,223 | 1,535 | |||
| Capital lease obligations | ✕ | ✕ | ✕ | 1,535 | ||
| Finance lease, liability | 5,454 | 5,573 | ✕ | |||
| Liabilities, other than long-term debt | 11,034 | 11,431 | 10,794 | |||
| Other liabilities | 11,034 | 11,431 | 10,794 | |||
| Operating lease, liability | 22,127 | 21,650 | ✕ | |||
| Other undisclosed noncurrent liabilities | 4,378 | |||||
| Total noncurrent liabilities: | 38,615 | 38,654 | 16,707 | |||
| Total liabilities: | 198,421 | 156,215 | 75,376 | |||
| Equity | ||||||
| Equity, attributable to parent | 741,090 | 726,034 | 415,159 | |||
| Common stock | 577 | 570 | 530 | |||
| Additional paid in capital | 1,690,151 | 1,632,046 | 1,246,857 | |||
| Accumulated other comprehensive loss | (53,551) | (68,623) | (75,194) | |||
| Accumulated deficit | (896,087) | (837,959) | (757,034) | |||
| Total equity: | 741,090 | 726,034 | 415,159 | |||
| TOTAL LIABILITIES AND EQUITY: | 939,511 | 882,249 | 490,535 | |||
Income Statement (P&L) ($ in thousands)
| 3/31/2021 TTM | 12/31/2020 | 12/31/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|
| Revenues | 527,205 | 311,332 | 12,737 | ||
| Cost of revenue | (37,531) | (130,933) | (5,986) | ||
| Cost of goods and services sold | (37,531) | (27,199) | (5,986) | ||
| Gross profit: | 489,674 | 180,399 | 6,751 | ||
| Operating expenses | (541,439) | (298,824) | (295,554) | ||
| Operating loss: | (51,765) | (118,425) | (288,803) | ||
| Nonoperating income (expense) | (2,160) | 110,309 | (1,318) | ||
| Investment income, nonoperating | 1,814 | 8,464 | 3,645 | ||
| Loss, foreign currency transaction, before tax | (3,974) | (2,272) | (4,963) | ||
| Other nonoperating income | 104,117 | ||||
| Interest and debt expense | (1,121) | (1,087) | (1,249) | ||
| Loss from continuing operations before income taxes: | (55,046) | (9,203) | (291,370) | ||
| Income tax expense (benefit) | (3,082) | 184 | (3,797) | ||
| Loss from continuing operations: | (58,128) | (9,019) | (295,167) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (58,128) | (9,019) | (295,167) | |
| Net loss available to common stockholders, diluted: | (58,128) | (9,019) | (295,167) | ||
Comprehensive Income ($ in thousands)
| 3/31/2021 TTM | 12/31/2020 | 12/31/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|
| Net loss: | (58,128) | (9,019) | (295,167) | ||
| Comprehensive loss: | (58,128) | (9,019) | (295,167) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 15,072 | 10,065 | (676) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (43,056) | 1,046 | (295,843) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.